BCR and neoplasm: Zanubrutinib exerts multifaceted effects on both innate and adaptive immunity by inhibiting BCR signaling pathways while simultaneously reprogramming myeloid cell functionality.26 Lenalidomide potentiates T-cell-mediated antitumor responses through cereblon-dependent degradation of lymphoid transcription factors and enhancement of immune synapse formation.27 The combined treatment effects likely restore immune defenses by expanding tumor-infiltrating immune cell densities, explaining better treatment responses to the R-ICE-X regimen.